Tiziana Life Sciences PLC Confirmation of Capital Reduction (8774J)
September 15 2016 - 2:00AM
UK Regulatory
TIDMTILS
RNS Number : 8774J
Tiziana Life Sciences PLC
15 September 2016
Tiziana Life Sciences PLC
("Tiziana" or the "Company")
Confirmation of Capital Reduction
London, 15 September 2016 - Tiziana Life Sciences plc (AIM:
TILS), a clinical stage biotechnology company focused on targeted
drugs to treat diseases in oncology and immunology, today
announces, further to its announcement dated 30 June 2016 the High
Court made an Order on 14 September 2016 ("Order") confirming the
capital reduction approved by shareholders pursuant to Resolution 9
passed at the Annual General Meeting ("AGM").
The Order has been registered at Companies House. Details of the
capital reduction were set out in the Notice of AGM dated 7 June
2016 and the proposal was approved by shareholders at the AGM held
on 30 June 2016.
Contacts:
Tiziana Life Sciences +44 (0)20
plc 7493 2853
Gabriele Cerrone, Chairman
and founder
Cairn Financial Advisers +44 (0)20
LLP 7148 7900
(Nominated adviser)
Liam Murray
+44 (0)20
Beaufort Securities Limited 7382 8300
(Broker)
Saif Janjua
+44 (0)20
FTI Consulting 3727 1000
Simon Conway / Natalie
Garland-Collins
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules that
treat human disease in oncology and immunology.
The Company is focused on its lead compound, milciclib, a
molecule which blocks the action of specific enzymes called
cyclin-dependent kinases (CDK) involved in cell division as well as
a number of other protein kinases. Milciclib is currently
completing phase II clinical trials for epithelial thymic carcinoma
and/or thymoma in patients previously treated with chemotherapy and
has filed an IND to enroll patients in an exploratory trial in
hepatic cellular carcinoma (HCC).
The Company is also in clinical development of foralumab.
Foralumab is the only fully human engineered anti-human CD3
antibody in clinical development. This phase II compound has
potential application in a wide range of autoimmune and
inflammatory diseases, such as ulcerative colitis, multiple
sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD),
psoriasis and rheumatoid arthritis, where modulation of a T-cell
response is desirable.
Tiziana Life Sciences' clinical development teams are working on
its Bcl-3 candidate, which has a prominent role in the metastasis
of mammary cancers, and has elucidated the mechanism of Bcl-3
action to be a regulator of cancer cell motility and has also
determined that Bcl-3 inhibition suppresses cell motility in
triple-negative, HER-2-positive PR- and ER-positive breast cancer
sub-types, suggesting that Bcl-3 may be a master regulator of this
metastatic property not only in aggressive breast cancers, but
across the clinical spectrum of breast disease. The Company is
preparing the IND package with the intention of progressing to
clinical trials early 2017.
For more information go to
http://www.tizianalifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFFFMLFMSELU
(END) Dow Jones Newswires
September 15, 2016 02:00 ET (06:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2023 to Apr 2024